BUZZ-Rezolute rises after FDA talks on rare low blood sugar disease drug

Reuters03-24
BUZZ-Rezolute rises after FDA talks on rare low blood sugar disease drug

** Shares of biotech firm Rezolute RZLT.O rise 7% to $2.57

** Co says it met the FDA to discuss next steps for its experimental drug ersodetug for congenital hyperinsulinism, a rare condition that causes dangerously low blood sugar in children

** Says late‑stage trial showed the drug reduced low blood sugar episodes from baseline, but did not beat placebo on its main goal

** Says trial results were affected by patient behavior, as families may have changed how closely blood sugar was monitored

** Adds FDA acknowledged challenges of trials in this disease and said it will review full data before deciding on approval filing or additional studies

** Early data from an ongoing extension study showed continued benefits - RZLT

** RZLT fell ~52% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment